Redefine Study: A Study Evaluating the Efficacy, Safety, and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder (Redefine)
A Phase 2b/3, Multicentre, Randomised, Double-blind, Controlled Trial, With an Open Label Extension, to Investigate the Efficacy, Safety, and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder
The Redefine Study (COMP202) is testing COMP360 to see if it may reduce post-traumatic stress disorder (PTSD) symptoms when administered alongside monitoring and support from a trained study team. COMP360 is a lab-made form of the naturally occurring chemical compound psilocybin.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Contact
Study Contact
- Name: www.redefineptsdstudy.com Redefine Study Call Center
- Phone Number: 202-459-9258
- Email: TheRedefineStudy@compasspathways.com
Study Locations
-
-
British Columbia
-
Kamloops, British Columbia, Canada, V2C 5T1
- Recruiting
- BC
-
North Vancouver, British Columbia, Canada, V7P2T4
- Recruiting
- BC
-
Penticton, British Columbia, Canada, V2A5L5
- Recruiting
- BC
-
-
-
-
Arizona
-
Tucson, Arizona, United States, 85704
- Recruiting
- AZ
-
-
California
-
Irvine, California, United States, 92612
- Recruiting
- CA
-
Los Angeles, California, United States, 90025
- Recruiting
- CA
-
Moorpark, California, United States, 93021
- Recruiting
- CA
-
San Jose, California, United States, 95124
- Recruiting
- CA
-
-
Florida
-
Miami, Florida, United States, 33125
- Recruiting
- FL
-
Orlando, Florida, United States, 32801
- Recruiting
- FL
-
-
Illinois
-
Chicago, Illinois, United States, 60612
- Recruiting
- IL
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02116
- Recruiting
- MA
-
-
Minnesota
-
Eden Prairie, Minnesota, United States, 55347
- Recruiting
- MN
-
-
Nebraska
-
Lincoln, Nebraska, United States, 68526
- Recruiting
- NE
-
-
Nevada
-
Las Vegas, Nevada, United States, 89119
- Recruiting
- NV
-
-
New York
-
New York, New York, United States, 10025
- Recruiting
- NY
-
The Bronx, New York, United States, 10461
- Recruiting
- NY
-
-
Ohio
-
North Canton, Ohio, United States, 44720
- Recruiting
- OH
-
-
Texas
-
Carrollton, Texas, United States, 75010
- Recruiting
- TX
-
-
Utah
-
Orem, Utah, United States, 84058
- Recruiting
- UT
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 18 years or older
- Diagnosed with PTSD at least 6 months ago
Exclusion Criteria:
- Diagnosed with certain psychiatric conditions such as bipolar disorder, schizophrenia, OCD, anorexia, or other conditions
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: 1 mg COMP360 psilocybin
|
COMP360 psilocybin administered with monitoring and support |
|
Experimental: 10 mg COMP360 psilocybin
|
COMP360 psilocybin administered with monitoring and support |
|
Experimental: 25 mg COMP360 psilocybin
|
COMP360 psilocybin administered with monitoring and support |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
COMP360 25 mg versus COMP360 1 mg change from Baseline to Week 8 in CAPS-5 total severity score
Time Frame: 8 weeks
|
The CAPS-5 (Clinician-Administered PTSD Scale for DSM-5) is a 30-item structured interview that yields a total severity score (0-80) reflecting PTSD symptoms. A higher CAPS-5 score indicates more severe, intense, and frequent PTSD symptoms. |
8 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- COMP202
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.